SafeTy and Efficacy of Preventative CoVID Vaccines (STOPCoV)

NCT05208983 UNKNOWN

The STOPCoV study is a decentralized study comparing COVID-19 vaccine specific antibody levels at 24 weeks after final vaccine dose. We plan to study the safety and immunogenicity of COVID-19 vaccine(s) in community dwelling persons 70 years and over relative to a younger group (aged 30 - 50 years).

Details

Lead sponsor	University Health Network, Toronto
Status	UNKNOWN
Enrolment	1286
Start date	2021-05-06
Completion	2024-04

Conditions

• COVID-19 Virus Infection
• Vaccine Response

Interventions

• mRNA Vaccines or Viral vector-based vaccines for COVID

Primary outcomes

• COviD-19 vaccine specific antibody levels — 24 weeks after the final vaccination.
  The ratio-normalized levels of anti-spike and anti-RBD IgG antibodies

Countries

Canada